Provided by Tiger Trade Technology Pte. Ltd.

PTC Therapeutics

66.06
-1.3100-1.94%
Post-market: 66.060.00000.00%19:47 EDT
Volume:792.89K
Turnover:52.68M
Market Cap:5.51B
PE:-108.30
High:68.48
Open:67.80
Low:65.91
Close:67.37
52wk High:90.87
52wk Low:57.74
Shares:83.46M
Float Shares:77.19M
Volume Ratio:0.88
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6100
EPS(LYR):7.78
ROE:-7740.12%
ROA:2.46%
PB:-33.34
PE(LYR):8.49

Loading ...

Mar 27, 2023

Proposed Sale Of Securities

144 - Report of proposed sale of securities
Mar 24, 2023

Major Issues Report

8-K - Current report
Mar 08, 2023

[Rev.]Annual Report

10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 21, 2023

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 21, 2023

Major Issues Report

8-K - Current report
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 09, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 06, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 01, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 09, 2023

Major Issues Report

8-K - Current report
Dec 16, 2022

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Dec 06, 2022

Major Issues Report

8-K - Current report
Oct 27, 2022

Major Issues Report

8-K - Current report
Oct 27, 2022

Major Issues Report

8-K - Current report
Oct 27, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Oct 18, 2022

Major Issues Report

8-K - Current report
Sep 07, 2022

Major Issues Report

8-K - Current report
Aug 15, 2022

Major Issues Report

8-K - Current report
Aug 04, 2022

Major Issues Report

8-K - Current report
Aug 04, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]